Herzilya, Israel – Renowned venture capital firm Pitango, headquartered in Herzilya, Israel, has achieved a significant milestone with the successful first closing of its second dedicated healthcare fund, known as Pitango HealthTech II. This initial close secured an impressive sum of $175 million, indicating robust investor confidence in the burgeoning health tech sector.
Pitango HealthTech II stands as Pitango’s specialized healthcare fund, focusing on investments across a broad spectrum of healthcare-related ventures, spanning from seed-stage startups to fully commercialized enterprises. The fund’s scope encompasses digital health, medical devices, techbio, diagnostics, foodtech, ag-tech, biotech, and life sciences, reflecting Pitango’s commitment to advancing innovations that positively impact the healthcare landscape.
Noteworthy inaugural investments from this fund include:
QuantHealth.ai: An AI-driven company specializing in clinical trial simulations aimed at expediting and de-risking drug development.
Nevia Bio: A FemTech enterprise at the forefront of developing an AI-based biomarker platform geared towards early detection of women’s health diseases.
These strategic investments align with Pitango HealthTech II’s mission to support cutting-edge ventures with transformative potential in the healthcare sector. Previous beneficiaries of Pitango’s investments encompass companies like Protai, Laguna Health, Vertos, Visby, Clew, and Magenta, underscoring the firm’s track record of nurturing innovative startups.
The fund’s leadership team comprises accomplished individuals:
Ittai Harel (Managing Partner)
Hila Karah (Managing Partner)
Dr. Jonathan Glazer (Partner)
Joel Schoppig (Senior Principal)
Dr. Seth Rudnick (Special Advisor)
Pitango HealthTech operates within the broader Pitango investment platform, alongside Pitango First and Pitango Growth Funds. Since its establishment in 1993, Pitango has actively invested in over 250 companies, with more than 85 of these entities subsequently going public or being acquired by strategic industry players.
